Medication Development

Highlights NIDA-funded research to develop vaccines against addiction to drugs such as cocaine, nicotine, phencyclidine (PCP), and methamphetamine.

Reports on study results indicating a medication prescribed for schizophrenia and manic phases of bipolar disorder shows promise as a cocaine addiction treatment.

Reports on a study investigating the effectiveness of a combined therapy of disulfiram and naltrexone for people who abuse cocaine and alcohol.

Reports on a new device that creates tiny painless punctures in the skin to allow medication to flow evenly from a skin patch into dermal capillaries and the bloodstream.

Reports on several drugs that may ward off depression and anxiety, common withdrawal symptoms from cocaine, based on an animal study.

Reports on two studies that demonstrate the promise of treating addiction with medications that alleviate drug-induced alterations in signaling by the neurotransmitter glutamate.

Reports on research investigating whether certain medications might strengthen patients' understanding and memory retention.

Announces the appointment of Dr. Phil Skolnick as NIDA’s director of the Division of Pharmacotherapies and Medical Consequences of Drug Abuse.

Announces three new NIDA National Advisory Council on Drug Abuse members and describes their drug abuse and addiction research experience.

Describes a study investigating the effectiveness of modafinil in enhancing sleep among cocaine abusers who are currently abstinent.